BECONASE HAYFEVER
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
22-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
BECLOMETASONE DIPROPIONATE MONOHYDRATE
Available from:
GlaxoSmithKline Consumer Healthcare (Ireland) Limited
Dosage:
50 Mcg/Dose
Pharmaceutical form:
Nasal Spray Suspension
Authorization date:
1999-09-17
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Beconase Hayfever nasal spray 50 micrograms per spray
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 100 mg spray contains beclometasone dipropionate monohydrate equivalent to 50 micrograms Beclometasone
Dipropionate Ph.Eur.
Excipients: Each 100 mg spray contains benzalkonium chloride solution equivalent to benzalkonium chloride 20
micrograms.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Nasal spray, suspension
An aqueous white opaque suspension in a plastic bottle fitted with a metering atomising pump and nasal applicator.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Beconase Hayfever prevents and relieves nasal congestion, sneezing and a runny, itchy nose due to hayfever and
other seasonal allergic conditions. Once nasal congestion is cleared the pressure and pain around the eyes is also
reduced.
4.2 Posology and method of administration
Regular usage is essential for full therapeutic benefit. Beconase Hayfever quickly starts to bring relief and reduce
swelling in the nose although it may take a few days to build up to its maximum effect.
Adults 18 years of age and over:
The recommended dose is two applications into
Read the complete document
